Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06624228 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
A Phase 3 study of Psoriatic Arthritis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 684
- Enrollment target
- 20
- Study locations
NCT06624228: Active Phase 3 study of Psoriatic Arthritis, sponsored by UCB Biopharma SRL.
NCT06624228 is a Phase 3 study of Psoriatic Arthritis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 684 participants, below the 839-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06624228, a Phase 3 study of Psoriatic Arthritis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 684 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Primary Outcome
The ACR50 response rate is based on a 50% or greater improvement of arthritis relative to Baseline. * TJC and SJC: 2-point scale (0=absent;1=present) • Patient's Global Assessment of Psoriatic Arthritis (PGA-PsA): 100 VAS (0=very good, no symptoms;100=very poor, severe symptoms) * Physician's Global Assessment of Psoriatic Arthritis (PhGA-PsA): 100 VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry ou
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bimekizumab
- DRUG Risankizumab
Study Locations (20)
Florida
- Pa0016 50630 - Clearwater
- Pa0016 50679 - Cutler Bay
- Pa0016 50685 - Fort Lauderdale
- Pa0016 50059 - Ormond Beach
- Pa0016 50324 - Plantation
- Pa0016 50678 - Zephyrhills
Arizona
- Pa0016 50662 - Gilbert
- Pa0016 50062 - Glendale
- Pa0016 50058 - Phoenix
- Pa0016 50131 - Sun City
California
- Pa0016 50654 - Covina
- Pa0016 50663 - San Diego
- Pa0016 50672 - Santa Monica
Illinois
- Pa0016 50651 - Skokie
- Pa0016 50650 - Willowbrook
Michigan
- Pa0016 50665 - Lansing
- Pa0016 50551 - Saint Clair Shores
Maryland
- Pa0016 50686 - Hagerstown
Minnesota
- Pa0016 50689 - Eagan
Missouri
- Pa0016 50682 - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2026-05-26 |
| Phase | Phase 3 |
What the registry record for NCT06624228 still lists
NCT06624228 is an interventional study that assigns participants to a tested intervention. The registered 684 participants enrollment target is mid-sized for trials with a published cap, below the 839-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06624228 names 20 study sites across 8 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06624228 about?
NCT06624228 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis". The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
What is the current status of trial NCT06624228?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 684 participants. The study started on 2024-10-21. Estimated completion is 2026-05-26.
What conditions does trial NCT06624228 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT06624228?
The interventions under investigation include: Placebo (DRUG), Bimekizumab (DRUG), Risankizumab (DRUG).
Who is sponsoring clinical trial NCT06624228?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06624228 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06624228's enrollment target sits among peer trials
684 11th of 48 higher than 38 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06795087 · 684 participants
Discharge Medication Use Post-Operatively in GU Cancer Patients
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- NCT05880199 · 685 participants
BSGM to Evaluate Patients With GI Symptoms
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI